Details of the Drug Formulations

General Information of Drug (ID: DMWP1BH)

• Drug Name: Tazemetostat Drug Info
• Synonyms: EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-

Indication

Disease Entry	ICD 11	Status	REF
Follicular lymphoma	2A80	Approved	[1]
Brain and central nervous system tumour	2A00.11	Phase 2	[2]
Malignant rhabdoid tumour	2A00.1Y	Phase 2	[3]
Mesothelioma	2C51.2	Phase 2	[4]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
Diffuse large B-cell lymphoma	2A81	Phase 1/2	[4]
Synovial sarcoma	2B5A	Phase 1	[4]

• Cross-matching ID:
  PubChem CID: 66558664
  CAS Number: 1403254-99-8
  TTD ID: D00EQL
  ACDINA ID: D01463

Full List of Drug Formulations Containing This Drug

Tazemetostat 200 mg tablet

Company	Formulation ID	FDA Description
Epizyme	F23299	Hydroxypropyl Cellulose; Lactose Monohydrate; Low-Substituted Hydroxypropyl Cellulose; Magnesium Stearate; Sodium Starch Glycolate; Hypromellose; Polyethylene Glycol; Red Iron Oxide; Talc; Titanium Dioxide

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)